|Bid||10.52 x 1000|
|Ask||10.54 x 1400|
|Day's Range||10.36 - 10.83|
|52 Week Range||5.50 - 15.00|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.11|
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology's P 2 SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.
Puma Biotechnology will release its financial results and host a conference call after the close of U.S. markets on August 6, 2020.